

Curriculum vitae for Thomas J. Montine, MD, PhD

Stanford Medicine Endowed Professor
and
Chair, Department of Pathology



Stanford University, Department of Pathology, 300 Pasteur Drive, Lane 235
Stanford, CA 94305-5324
<https://twitter.com/StanfordPath>

Phone: 650-723-5252 tmontine@stanford.edu

PROFESSIONAL SUMMARY

Dr. Montine received his education at Columbia University (BA in Chemistry), the University of Rochester (PhD in Pharmacology), and McGill University (MD and CM). His postgraduate medical training was at Duke University, and he was junior faculty at Vanderbilt University where he was awarded the Thorne Professorship in Pathology. In 2002, Dr. Montine was appointed as the Alvord Endowed Professor in Neuropathology and Director of the Division of Neuropathology at the University of Washington. He was Director of the University of Washington Alzheimer's Disease Research Center, one of the original 10 Centers in the US, and passed that responsibility to able colleagues. In 2010, Dr. Montine was appointed Chair of the Department of Pathology at the University of Washington. In 2016, Dr. Montine was appointed Chair of the Department of Pathology at Stanford University and the Stanford Medicine Endowed Professor in Pathology.

Dr. Montine was the 2015 President of the American Association of Neuropathologists, and led or co-led recent NIH initiatives to revise diagnostic guidelines for Alzheimer's disease (NIA), develop research priorities for the National Alzheimer's Plan (NINDS and NIA), and develop national research priorities for Parkinson's Disease (NINDS). He is the founding Director of the Pacific Udall Center, one of 9 NINDS-funded Morris K. Udall Centers of Excellence for Parkinson's Disease Research, that focuses on a vision for precision health that comprises functional genomics, development of surveillance tools for pre-clinical detection, and discovery of molecularly tailored therapies.

The focus of the Montine Laboratory is on the molecular and biochemical bases of cognitive impairment in aging and neurodegenerative diseases with the goal of defining key pathogenic steps and thereby new therapeutic targets. The Montine Laboratory addresses these prevalent, unmet medical needs through a combination of neuropathology, biomarker development and application early in the course of disease, and experimental studies that test hypotheses concerning specific mechanisms of neuron injury and approaches to neuroprotection.

Dr. Montine is among the top recipients of NIH funding for all Department of Pathology faculty in the United States. PubMed lists 694 publications for Dr. Montine, Google Scholar estimates his H-Index as 121 and total citations as > 79,000. NIH iCite calculates Dr. Montine's weighted relative citation ratio as 3453.

EDUCATION

MD and Master of Surgery (CM)	McGill University, Montréal, Québec	June 1991
PhD in Pharmacology	University of Rochester, Rochester, NY	October 1988
BA in Chemistry	Columbia University, New York, NY	May 1983

PROFESSIONAL TRAINING

Neuropathology Fellowship	Duke University, Durham, NC	1993 – 1995
Pathology Residency	Duke University, Durham, NC	1991 – 1993

CURRENT APPOINTMENTS

Stanford University	Chair, Department of Pathology	2016 – present
Stanford University	Stanford Medicine Endowed Professor of Pathology	2016 – present

PREVIOUS APPOINTMENTS

University of Washington, Seattle, WA	Chair, Department of Pathology	2010 - 2016
	Acting Chief of Service, Pathology, Harborview Medical Center, UW Medicine	2010 – 2011
	Director, Division of Neuropathology	2002 – 2010
	Alvord Endowed Chair and Professor of Pathology	2002 - 2016
Vanderbilt University Nashville, TN	Margaret and George Thorne Professorship in Pathology	2000 – 2002
	Associate Professor of Pathology Associate Professor of Pharmacology	1999 – 2002
	Assistant Professor of Pathology Assistant Professor of Pharmacology	1996 – 1999

CLINICAL RESPONSIBILITIES

Neuropathology Attending	Stanford Health Care and Stanford Children's Health	2016 - present
	UW Medicine and Seattle Children's Medical Center	2002 - 2016
	Vanderbilt University Medical Center	1996 - 2002

PROFESSIONAL HONORS AND AWARDS

Leo Kaplan, M.D., Lecture in Anatomic Pathology, Cedars-Sinai Medical Center	2019
President of the American Association of Neuropathologists	2015
Dr. Raymond Adams Lecture, Massachusetts General Hospital	2014
Saul Korey Award from American Association of Neuropathologists	2014
Turken International Lecture, UCLA	2011
Vice President of the American Association of Neuropathologists (AANP)	2007
“Teacher of the Quarter” Award University of Washington School of Medicine	2004
American Society of Investigational Pathologists (FASEB), Merit Award	1996
Neurotoxicology Specialty Section Postdoctoral Award, Society of Toxicology	1995
Korey Research Fellow Award, XII International Congress of Neuropathology	1994
Wiley Forbus Resident Research Award, North Carolina Society of Pathologists	1994
Hewlett-Packard Award for Academic Excellence, McGill University	1991
University Scholar, McGill University Faculty of Medicine, Graduating Class 1991	1991
Ciba-Geigy Research Scholarship	1989
McGill Faculty Research Scholarships, Medical Research Council of Canada	1989, 1990
McGill University Medical Student Research Scholar	1989

MAJOR TRAINING PROGRAM AND TEACHING RESPONSIBILITIES

University of Washington, Seattle, WA

Director, Environmental Pathology and Toxicology Training Program	2007 – 2014
Director, Neuropathology Training Program	2002 – 2010
Section Director, HuBio546 “Neuropathology,” School of Medicine	2003 – 2006
Course Director, Path513 “Molecular Mechanisms of Neurodegeneration”	2003 – 2010

Vanderbilt University, Nashville, TN

Director, Graduate Studies, University Neuroscience Training Program	2000 – 2002
Director, Neuropathology Training Program	1997 – 2002
Section Director, Pathology 501 “Neuropathology”	1997 – 2002
Section Director, Pharm 320 “Targets and Mechanisms: Nervous System”	1998 – 2002
Section Director, Pharm 321 “Medical Pharmacology: Nervous System”	1998 – 2002
Section Director, Neurosci 326 “Molecular Mechanisms of Neural Diseases”	1998 – 2002
Doctoral Qualifying Examination Committee, Department of Pathology and Neuroscience Training Program	1998 – 2002

RESEARCH FUNDING**Current Awards**

	Dates of Award
1. Department of Health and Human Services, NIH U01 AG032984 <i>Alzheimer's Disease Genetic Consortium</i> PI: Gerard D. Schellenberg Co-PI: Thomas J. Montine, MD, PhD	04/2009 – 03/2025
2. Department of Health and Human Services, NIH P30 AG049638 <i>Wake Forest Alzheimer's Disease Core Center</i> PI: Suzanne Craft Co-Investigator: Thomas J. Montine, MD, PhD	07/2016 – 06/2022
3. Department of Health and Human Services, NIH R01 NS094003 <i>Neuropathological Characterization of "CTE"</i> MPIs: Douglas H. Smith, MD John Trojanowski, MD, PhD Co-Investigator: Thomas J. Montine, MD, PhD	04/2016 – 03/2022
4. Michael J. Fox Foundation, Grant ID 14706 <i>Parkinson's Progression Marker Initiative Neuropathology Core</i> PIs: Tatiana Foroud, PhD, and Thomas Montine, MD, PhD	06/2017 – 05/2022
5. Department of Health and Human Services, NIH R01 AG056287 <i>The Phenotypic Landscape of Cognitive Decline as Revealed by Next-Generation Multiplexed Ion Beam Imaging</i> MPIs: S Bendall, PhD, M Angelo, PhD, and TJ Montine, MD, PhD	08/2017 – 04/2022
6. Department of Health and Human Services, NIH R01 AG057915 <i>MIRIAD - Multiplexed Imaging of Resilience in Alzheimer's Disease</i> MPIs: S Bendall, PhD, M Angelo, PhD, and TJ Montine, MD, PhD	09/2017 – 05/2022
7. Department of Health and Human Services, NIH UF1 AG057707 <i>Neuropathologic substrates for motor and cognitive impairment in three existing cohort studies of Alzheimer's disease and related dementias</i> MPIs: Thomas J. Montine, MD, PhD and Lon R. White, MD, MPH	09/2017 – 03/2022
8. Department of Health and Human Services, NIH RF1 AG058829 <i>Effects of Western and Mediterranean Diets on Metabolic and Neuro-pathologic Risk Factors for Alzheimer's Disease in Nonhuman Primates</i> MPIs: Suzanne Craft, PhD and Carol Shively, PhD Co-Investigator: Thomas J. Montine, MD, PhD	08/2018 – 07/2022
9. Department of Health and Human Services, NIH U24 AG057437 <i>Alzheimer's Clinical Trials Consortium (ACTC)</i> MPIs: Paul Aisen, MD Ronald Petersen, MD Reisa Sperling, MD Co-Investigator: Thomas J. Montine, MD, PhD	12/2017 – 11/2022
10. Farmer Family Foundation <i>Optimizing Small Molecules to treat Parkinson's disease</i> PI: Thomas J. Montine, MD, PhD	03/2019 – 05/2022

Curriculum Vitae for Thomas J. Montine, MD, PhD

11. **Department of Health and Human Services, NIH P30 AG062715** 05/2019 – 03/2024
Wisconsin Alzheimer's Disease Research center
 PI: Sanjay Asthana MD
 Co-Investigator: Thomas J. Montine, MD, PhD

12. **Department of Health and Human Services, NIH R01 AG062695** 06/2019 – 03/2024
Identifying the Genetic Etiology of Neuropathology for Alzheimer Disease and Related Dementias
 MPIs: Gary Beecham, PhD Thomas Montine, MD, PhD

13. **Department of Health and Human Services, NIH U19 AG065156** 02/2020 – 01/2025
Next Generation Translational Proteomics for Alzheimer's and Related Dementias
 MPIs: Michael MacCoss, PhD Thomas J. Montine, MD, PhD

14. **Department of Health and Human Services, NIH R01 AG066490** 02/2020 – 01/2025
Mapping Molecular and Phenotypic Interactions in Alzheimer's Disease
 PI: Stephen Montgomery, PhD
 Co-Investigator: Thomas J. Montine, MD, PhD

15. **Department of Health and Human Services, NIH R01 AG068279** 08/2020 – 07/2025
Uncoupling Age- Versus Cognitive-Related Cellular Senescence in Alzheimer's Disease
 PI: Sean Bendall, PhD
 Co-Investigator: Thomas J. Montine, MD, PhD

16. **Alzheimer's Drug Discovery Foundation, 202001-2019931** 03/2021 – 02/2022
Blood-based immune biomarkers for Alzheimer's disease diagnosis and its early detection
 PI: Thomas J. Montine, MD, PhD

17. **Department of Health and Human Services, NIH R01 AG062706-03S1** 03/2021 – 01/2022
Diagnosis and Risk Factors of Hippocampal Sclerosis of Aging: A Common Alzheimer's Mimic in the Oldest Old
 PI: Seyed Ahmad Sajjadi, MD
 Co-Investigator: Thomas J. Montine, MD, PhD

18. **Department of Health and Human Services, NIH U01 AG072573** 07/2021 – 06/2026
Multi-omic Functional Assessment of Novel AD Variants Using High-Throughput and Single-Cell Technologies
 MPIs: Thomas J. Montine, MD, PhD Anshul Kundaje, PhD Stephen Montgomery, PhD

Past Awards

1. **Department of Health and Human Services, NIH F32 ES05625** 9/1993 – 9/1995
Toxicant-enhanced autoxidation of dopa and dopamine
 PI: Thomas J. Montine, MD, PhD

2. **American Foundation for Aging Research** 7/1998 – 6/2000
Lipid peroxidation and APOE in Alzheimer's disease
 PI: Thomas J. Montine, MD, PhD

3. **Department of Health and Human Services, NIH K08 AG00774** 7/1996 – 6/2001

Curriculum Vitae for Thomas J. Montine, MD, PhD

Crosslinking of tau and apoE in Alzheimer's disease

PI: Thomas J. Montine, MD, PhD

4. **Alzheimer's Association**
Quantification of brain oxidative damage in Alzheimer's disease
 PI: Thomas J. Montine, MD, PhD

8/1998 – 8/2001
5. **Department of Health and Human Services, NIH U01 MH061971**
Targeted mutagenesis of the mouse genome and neural phenotypes
 PI: Dan Goldwicz, PhD (University of Tennessee, Memphis)
 Project: *Aging Domain*. Project Leader: Thomas J. Montine, MD, PhD

9/2000 – 8/2003
6. **University of Washington, Dean's Award** sponsored by
 Alzheimer's Disease Public Awareness Fund, Seattle, WA.
Eicosanoids and Oxidative Damage in Alzheimer's Disease.
 PI: Thomas J. Montine, MD, PhD

12/2002 – 12/2004
7. **Department of Health and Human Services, NIH R01 AG16835**
Lipid peroxidation and APOE in Alzheimer's disease.
 PI: Thomas J. Montine, MD, PhD

7/1999 – 6/2004
8. **Department of Health and Human Services, NIH R01 ES10196**
Catechol thioethers in Parkinson's disease
 PI: Thomas J. Montine, MD, PhD (4/2000 to 3/2005)
Transferred PI to Dr. Jing Zhang, MD, PhD in 2010

4/2000 – 3/2010
9. **Department of Health and Human Services, NIH P50 AG05144**
Alzheimer's Disease Research Center
 PI: William R. Markesbery, MD, PhD (University of Kentucky)
 Project: *Lipid peroxidation, antioxidants and Alzheimer's disease*
 Project Leader: Thomas J. Montine, MD, PhD

5/2000 – 4/2005
10. **Department of Health and Human Services, NIH R01 AG024011**
Lipid oxidation products in Alzheimer's disease
 PI: Thomas J. Montine, MD, PhD

9/2003 – 8/2008
11. **Department of Health and Human Services, NIH R01 NS48595**
Characterization of dementia with Lewy bodies: A collaborative study
 PI: Thomas J. Montine, MD, PhD

9/2003 – 8/2008
12. **Department of Health and Human Services, NIH R01 AG024010**
NSAIDs in prevention of Alzheimer disease
 PI: John Breitner, MD, MPH
 Co-investigator: Thomas J. Montine, MD, PhD

9/2003 – 8/2008
13. **Department of Health and Human Services, NIH R21 AG029808**
Proteomic discovery in parkinson-dementia complex of Guam
 PI: Thomas J. Montine, MD, PhD

7/2007 – 6/2009
14. **Department of Health and Human Services NIH 2P50 GM015431**
Research Center for Pharmacology and Drug Toxicology
 PI: Dr. John Oates (Vanderbilt University)
Prostaglandin D₂ receptor
 Project Leader, Thomas J. Montine, MD, PhD

7/2006 – 6/2010
15. **Department of Health and Human Services, Center for Disease**

5/2004 – 2010

Control and Prevention, Standing Contract

Emerging neurodegenerative diseases in WA State

PI: Thomas J. Montine, MD, PhD

16. **Department of Health and Human Services, NIH R01 ES16754** 7/2009 – 6/2014
Toxicants and innate immunity in models of Parkinson's disease
 PI: Thomas J. Montine, MD, PhD

17. **Department of Health and Human Services, NIH T32 ES007032** 7/2008 – 6/2018
Environmental Pathology/Toxicology Training Program
 PI: Thomas J. Montine, MD, PhD
Transferred PI to Dr. Jing Zhang, MD, PhD in 2015

18. **Department of Health and Human Services, NIH T32 AG000258** 7/2009 – 6/2015
Neurobehavior, Neuroendocrinology and Genetics of AD
 PI: Thomas J. Montine, MD, PhD
Transferred PI to Dr. Elaine Peskind, MD, in 2014

19. **Department of Health and Human Services, NIH R01 AG023801** 7/2005 – 6/2016
Pharmaco-neuropathology of aging and dementia
 PI: Thomas J. Montine, MD, PhD
Transferred PI to Joshua A. Sonnen, MD in 2011

20. **Department of Health and Human Services, NIH R37 AG10880** 7/2010 – 6/2015
Glucose regulation and memory in Alzheimer's disease
 PI: Suzanne Craft, PhD
 Co-Investigator: Thomas J. Montine, MD, PhD

21. **Department of Health and Human Services, NIH P50 AG05136** 5/1985 – 4/2020
Alzheimer's Disease Research Center
 Center Director: Thomas J. Montine, MD, PhD
Dr. Montine was Center Director from 2012 to 2016, and successfully renewed the Center in 2015 before relinquishing the award to colleagues at UW when he moved to Stanford University in May 2016.

22. **Department of Health and Human Services, NIH P50 AG033514** 05/2009 – 04/2019
Wisconsin Alzheimer's Disease Research Center
 Center Director: Sanjay Asthana
 Neuropathology Core Leader: Thomas J. Montine, MD, PhD
Dr. Montine was Core Co-Leader from 2009 to 2016, before relinquishing the renewed award to newly recruited colleagues at University of Wisconsin when he moved to Stanford University in May 2016.

23. **Department of Health and Human Services, NIH R01 AG048232** 09/2014 – 06/2019
Targeting the kynurenine pathway in Alzheimer's disease
 MPIs: Katrin I. Andreasson, MD, and Thomas J. Montine, MD, PhD

24. **Department of Health and Human Services, NIH U01 AG046161** 09/2014 – 04/2019
Discovery of novel proteomic targets for treatment of Alzheimer's disease
 MPIs: Allan I. Levey, MD, PhD, David A. Bennett, Daniel H. Geschwind, MD, PhD, Thomas J. Montine, MD, PhD, John Q. Trojanowski, MD, PhD, Juan Troncoso, MD

25. **Department of Health and Human Services, NIH U01 AG006781** 05/1986 – 04/2020
Alzheimer's Disease Patient Registry (ADPR/ACT)
 MPIs: Eric B. Larson and Paul K. Crane

Curriculum Vitae for Thomas J. Montine, MD, PhD

Co-Investigator: Thomas J. Montine, MD, PhD

Dr. Montine relinquished remaining 4 years of funding to Dr. Keene when he relocated to Stanford University in May 2016

26. **Department of Health and Human Services, NIH U01 AG046871** 04/2013 – 03/2017
Neuropathologic research on dementia using Nun Study and HAAS data
 MPIs: Thomas J. Montine, MD, PhD and Lon R. White, MD, MPH

27. **Department of Health and Human Services, NIH R01 AG031892** 08/2009 – 05/2018
White matter damage in age-related cognitive decline
 PI: Thomas J. Montine, MD, PhD

28. **Google, Inc** 02/2019 – 6/2020
Stanford Anatomic Pathology & Google Brain Collaboration
 PI: Thomas J. Montine, MD, PhD

29. **Department of Health and Human Services, NIH P30 AG059295** 09/2018 – 06/2023
Native Alzheimer's Disease Resource Center for Minority Aging Research (NAD-RCMAR)
 MPIs: Dedra Buchwald, MD Spero Manson, PhD Thomas Montine, MD, PhD
In 2020, with approval of NIH, Dr. Montine revised his status to consultant.

30. **Department of Health and Human Services, NIH R01 AG060747** 09/2018 – 05/2023
The Stanford Extreme Phenotypes in Alzheimer's Disease (StEP AD) Cohort
 PI: Michael Greicius, MD
 Co-Investigator: Thomas J. Montine, MD, PhD

31. **Department of Health and Human Services, NIH UF1 AG053983** 07/2016 – 06/2020
Cognitive resilience to Alzheimer neuropathologic changes in the Honolulu-Asia Aging Study and the Nun Study
 MPIs: Thomas J. Montine, MD, PhD, and Lon White, PhD

32. **Michael J. Fox Foundation, Grant ID 6709.03** 07/2019 – 07/2020
Mechanistic understanding of the LRRK2-PAK6-PPP1/PPP2 pathway
 MPIs: Jean-Marc Taymans, PhD Marie-Christine Chartier-Harlin, PhD
 Elisa Greggio, PhD Arjan Kortholt, PhD Thomas Montine, MD, PhD
 R. Jeremy Nichols, PhD

33. **Michael J. Fox Foundation, Grant ID 17358** 03/2019 – 12/2020
Quantitative imaging techniques to evaluate the contribution of LRRK2 kinase activity in idiopathic Parkinson's disease
 PI: Thomas J. Montine, MD, PhD

34. **Department of Health and Human Services, NIH R01AG021055-16S2** 04/2019 – 05/2020
Administrative Supplement to R01AG21055 Clinical, Imaging, and Pathological Studies in the Oldest Old: The 90+ Study
 PI: Claudia Kawas, MD and Maria Corrada-Bravo, SCD
 Co-Investigator: Thomas J. Montine, MD, PhD

35. **Department of Health and Human Services, NIH P30 AG066515** 05/2016 – 03/2025
 (original award: P50 AG047366)
Stanford Alzheimer's Disease Research Center
 PI: Victor Henderson

Curriculum Vitae for Thomas J. Montine, MD, PhD

Neuropathology Core Co-Leader: Thomas J. Montine, MD, PhD
In September 2020, Dr. Montine transferred responsibility for this project to his colleague Dr. Inma Cobos.

36. **Department of Health and Human Services, NIH P50 NS062684** 08/2009 – 06/2021
Pacific Udall Center of Excellence for Parkinson's Disease Research
 Center Director: Thomas J. Montine, MD, PhD

37. **Department of Health and Human Services, NIH 5P30 AG019610-21** 07/2020 – 06/2021
Arizona Alzheimer's Disease Core Center - COVID-19 Supplement
 PI: Eric Reiman, MD (parent award) Thomas Beach, MD (supplement PI)
 Co-Investigator: Thomas J. Montine, MD, PhD

38. **Department of Health and Human Services, NIH R56 AG063885** 08/2019 – 07/2021
Leveraging Glycomics to Characterize a Molecular Signature of Alzheimer's Disease
 MPIS: David Muddiman, PhD Erin Baker, PhD Michael MacCoss, PhD
 Thomas J. Montine, MD, PhD

39. **Department of Health and Human Services, NIH RF1 AG053959** 08/2016 – 08/2021
Molecular Phenotyping in Alzheimer's Disease
 MPIS: Thomas J. Montine, MD, PhD Michael MacCoss, PhD,
 and Eric Larson, MD

40. **Department of Health and Human Services, NIH U41 HG009649** 09/2017 – 09/2021
Clinical Genome Resource (ClinGen)
 MPIS: Thomas Montine, MD, PhD Sharon Plon, MD

CONSULTATION	
Allen Institute for Brain Science, Seattle, WA	
Amgen, Thousand Oaks, CA	
Avid Radiopharmaceuticals, Philadelphia, PA	
Biosource, Camarillo, CA	
Bristol-Myers Squibb, PA	
Eisai, Andover, MA	
Epicor, Sunnyvale, CA	
General Electric Health Systems	
Genentech, South San Francisco, CA	
Google, Mountain View, CA	
LINK Medicine, Boston, MA	
Martek Biosciences, Baltimore, MD	
Medisyn, Minneapolis, MN	
Michael J. Fox Foundation, New York, NY	

Nines, Palo Alto, CA
Philips, Amsterdam, Netherlands
Seabourne, Portland, OR
T3D Therapeutics, The PIONEER Study, North Carolina
Xenova, London, England
Xygen Therapeutics, Petaluma, CA

MAJOR COMMITTEE RESPONSIBILITIES

State, National, and International

Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Working Group	2020-present
Scientific Advisory Board, Alzheimer's Drug Discovery Foundation	2020 - 2021
Scientific Advisory Board, Van Andel Institute	2020 - 2024
Scientific Advisory Committee, Duke University	2018
External Advisory Committee, Alzheimer's Disease Research Center, UCSF	2017 - present
External Advisory Committee, Alzheimer's Disease Research Center, Emory University	2016 - present
Dementias Platform - United Kingdom	2015 - 2017
Alzheimer's Association International Conference, Scientific Program Committee	2015 - 2018
Governor's Working Group to Develop Washington State Plan to Address Alzheimer's Disease, member	2014 - 2016
American Association of Neuropathologists, President	2015
External Advisory Committee, Massachusetts Alzheimer's Disease Research Center, Harvard University	2014 - present
Blue Ribbon Panel, University of California Irvine, Department of Pathology	2013
Alzheimer Association of Western Washington, Member of Executive Board	2012 - 2016
National Parkinson's Disease Resource, NINDS, Steering Committee, Chair	2012 - 2016
External Advisory Committee, Alzheimer's Disease Research Center, University of California, Irvine	2011 – 2018
Studies to Prevent Alzheimer's Disease (StoP-AD), McGill University, Member	2011 – 2015
Alzheimer's Prevention Initiative, Advisory Board, Chair	2011 – 2015
University of Minnesota, Institute for Translational Neuroscience, Presidential Review Panel, Chair	2011
Arizona Alzheimer's Consortium, Advisory Board, Member	2011 - present
Alzheimer's Drug Discovery Foundation, Scientific Advisory Board, Member	2010 – 2013
<i>Aging and Dementia</i> , American Association of Neurologists 62 nd Annual Meeting, Toronto, Co-Chair	2010
American Federation for Aging Research National Scientific Advisory Council	2009 – 2014

Curriculum Vitae for Thomas J. Montine, MD, PhD

External Advisory Committee, Dominantly Inherited Alzheimer Network, Washington University in St. Louis, Member	2009 – present
<i>Aging and Dementia</i> , American Association of Neurologists 61 st Annual Meeting, Seattle, co-Chair	2009
<i>Aging and Dementia: Basic Science and Neuropathology</i> , American Association of Neurologists 60 th Annual Meeting, Chicago	2008
<i>Alzheimer's Disease</i> , American Association of Neuropathologists, Experimental Biology, San Diego, co-Chair	2008
Executive Committee and co-Chair of Neuropathology Committee, Alzheimer's Disease Center Genetic Consortium, Member	2007 –2018
College of American Pathologists, Neuropathology Committee, Member	2007 – 2010
External Advisory Committee, Alzheimer's Disease Center, Duke University, Member	2007 – 2012
External Advisory Committee, Alzheimer's Disease Research Center, University of Pittsburgh, Member	2007 – 2016
Neuropathology Symposium, <i>Neurodegenerative Diseases</i> , Experimental Biology (FASEB) Washington, DC, Chair	2007
College of American Pathologists, Neuropathology Committee, Member	2007 – 2011
External Advisory Committee, Alzheimer's Disease Center, University of Kentucky, Chair	2006 – 2010
Washington State Department of Health, Advisory Council on Prion Diseases	2004 - 2016
Neuropathology Symposium, <i>Mechanisms of Neuronal Cell Death</i> , Experimental Biology (FASEB) San Diego, CA, Chair	2005
External Advisory Committee, Alzheimer's Disease Center, UCLA, Member	2004 – 2015
Experimental Biology (FASEB) Muller Conference "Inflammatory Mechanisms in CNS Diseases", Washington, DC, Chair	2004
American Association of Neuropathologists Meeting "Neurodegenerative Diseases", Orlando, FL, Chair	2003
Neuropathology Symposium, Experimental Biology (FASEB), San Diego, CA, Chair	2003
FASEB Program Committee for Experimental Biology, Member	2003 – 2005
American Association of Neuropathologists, Award Committee, Member	1999 – 2001
American Association of Neuropathologists, Constitution Committee, Member and Chair	1998 – 2001

EDITORIAL BOARDS

<i>Journal of Neuropathology and Experimental Neurology</i>	1997 – 2003
<i>Journal of Alzheimer's Disease</i>	2001 – 2008
<i>The American Journal of Pathology</i>	2004 – 2013
<i>Brain Pathology</i> , Senior Editor	2006 – 2012

<i>Journal of Neuroinflammation</i>	2007 – 2012
<i>Laboratory Investigation</i>	2009 – 2018

SERVICE TO NATIONAL INSTITUTES OF HEALTH

National Institutes of Health, Member or Chair, Various Special Emphasis and <i>ad hoc</i> Panels	1997 – present
Charter Member of MDCN-5 IRG “Molecular Neuropharmacology and Signaling”	1999 – 2006
Invited Workshop on "Biomarkers of Dementia"	1999
Center for Scientific Review, <i>Ad hoc</i> member of ALTX-3 IRG	2000
Invited Workshop by NIA on Lewy Body Diseases with Dementia	2004
Chair, Resource Allocation Review Committee for the Alzheimer’s Disease Neuroimaging Initiative	2005 – present
Invited Workshop on "Vascular Bases of Cognitive Impairment"	2006
Neurodegenerative Diseases of Guam and Mariana Islands, Scientific Advisory Board	2007
Invited Workshop on "Mechanisms of Apolipoprotein E isoforms in Dementia"	2008
National Alzheimer’s Disease Coordinating Center Neuropathology Committee, NIA, Member	2008 – 2009
NIEHS Health Sciences Review Committee, Charter Member	2009 – 2013
Invited NINDS Workshop on “Biomarkers of Lewy Body Disease” and Chair of Biofluid Biomarkers Session	2010
Invited NINDS Workshop on “Parkinson’s Disease Biomarker Strategic Planning” and Chair of Pre-motor Biomarkers Session	2010
Tenure advisory committee, <i>ad hoc</i> member, NIEHS	2010
NIA–Alzheimer’s Association Committee on Pre-Clinical Alzheimer’s Disease, Member	2010
NIA–Alzheimer’s Association Committee to Revise Pathologic Criteria for Alzheimer’s Disease, co-Chair	2010 – 2011
National Alzheimer’s Disease Coordinating Center Neuropathology Committee, NIA, Member and Chair	2010 – 2013
NIA Neuroscience of Aging Review Committee, Charter Member	2011 – 2015
NINDS Udall Center Coordinating Committee, Executive Committee Member	2012 - 2014
NINDS Udall Center Coordinating Committee, Executive Committee Chair	2013 and 2019
NINDS National Brain and Tissue Resource for Parkinson’s Disease and Related Disorders, Steering Committee, Chair	2012 - 2016
NIH Alzheimer’s Disease-Related Dementias Workshop, Scientific Chair (NINDS with collaboration from NIA)	2013
NIA Division of Neuroscience Program Review Committee, Member	2012 - 2013

NINDS Workshop on “Vascular Interactions with Alzheimer’s Disease”	2014
NINDS Parkinson’s Disease 2014, Scientific Chair (NINDS)	2014
National Alzheimer’s Disease Coordinating Center Steering Committee, NIA, Chair	2014-2015
NIA-AA “Research Framework: Toward a biological definition of Alzheimer’s disease”	2016-2018
NINDA MARK-VCID External Advisory Committee	2017-2021
NIH Workshop on “Prions and Transmissibility of Neurodegenerative Diseases”	2018
NIA Workshop on “Hippocampal Sclerosis and TDP-43 Proteinopathy”	2018
NIA Workshop on “Neuropathological Diagnosis of Chronic Traumatic Encephalopathy (CTE): Next Steps”	2019

INVENTIONS

“Enhanced microglial phagocytosis of amyloid- β peptides and α -synuclein by suppression of prostaglandin E₂ receptor subtype 2 (EP2)-mediated signaling” UW Office of Technology Licensing # 7351D

“Myeloprostanes: Biomarkers for Free Radical Attacks on Adrenate” UW Office of Technology Licensing #7529D

“Alzheimer’s Diagnostic Method” United States Patent and Trademark Office by Application No. 63/001,195 filed 27 March 2020

“Enantiomers Selective Action on Neurotransmission” United States Patent and Trademark Office by Application No. 63/170,773 filed 5 April 2020

“Selective Indazole LRRK2 Inhibitors and Methods for Use Thereof” United States Patent and Trademark Office Application No. 63/213,435 filed 20 July 2021

“Selective Pyrazole LRRK2 Inhibitors and Methods for Use Thereof” United States Patent and Trademark Office Application No. 63/223,337 filed 2 August 2021

INVITED PRESENTATIONS

1. National Institute of Environmental Health Sciences, Research Triangle Park, NC, 1995. *Catechol oxidation in the pathogenesis of Parkinson’s disease.*
2. Oklahoma Center for Neurosciences Fifth Annual Symposium, Oklahoma City, OK, 1996. *Products of lipid peroxidation in the pathogenesis of Alzheimer’s disease.*
3. University of Kentucky, Sanders-Brown Center on Aging and Alzheimer’s Disease Research Center, Lexington, KY, 1996. *Aging, APOE, and Alzheimer’s disease.*
4. Duke University Medical Center, Joseph and Kathleen Bryan Alzheimer’s Disease Research Center, Durham, NC, 1997. *Lipid peroxidation and APOE in Alzheimer’s disease.*
5. National Institutes of Health, Meharry Medical College, University of Kentucky, and Vanderbilt University Combined Symposium on Alzheimer’s Disease, Nashville, TN, 1997. *Pathogenic mechanisms in Alzheimer’s disease and the neuropathology of dementing illness.*
6. University of Pennsylvania, Department of Pathology, Philadelphia, PA, 1998. *Lipid*

peroxidation and APOE in Alzheimer's disease.

7. Hoffmann-LaRoche, Neuroscience Research Division, Basel, Switzerland, 1998. *Lipid peroxidation in age-related neurodegenerative diseases.*
8. Washington University in St. Louis, Alzheimer's Disease Research Center, 1998. *Lipid peroxidation and Alzheimer's disease.*
9. University of Kentucky, Sanders-Brown Center on Aging and Alzheimer's Disease Research Center, Lexington, KY, 1998. *Quantification of brain oxidative damage in Alzheimer's disease.*
10. Alzheimer's Disease and Related Disorders Association, Annual Meeting, Palm Beach, FL, 1999. *Research in Alzheimer's disease.*
11. National Institutes of Health, Neuroimaging and Biological Markers for Alzheimer's Disease Diagnosis and Progression, Bethesda, MD, 1999. *Cerebrospinal fluid isoprostanes in Alzheimer's disease.*
12. University of Kentucky, Department of Pathology, September 1999. *Oxidative damage in age-related neurodegenerative diseases.*
13. Ninth North American ISSX Meeting, Nashville, TN, 1999. *Catechol-thioethers in Parkinson's disease.*
14. Duke University Medical Center, Department of Pathology, 2000. *Reactive intermediates in neurodegeneration.*
15. American Geriatrics Society/American Federation for Aging Research Annual Scientific Meeting, Nashville, TN, 2000. *Neuroprotectants from the lipid peroxidation product 4-hydroxy-2-nonenal.*
16. American Federation of Aging Research Grantees Conference, Boston, MA, 2000. *Quantification of neuronal oxidative damage in Alzheimer's disease.*
17. Alzheimer's Association of Tennessee Annual Meeting, Knoxville, TN, 2000. *Current research into Alzheimer's disease.*
18. Community Forum, Center in Molecular Toxicology of Vanderbilt University, Cumberland Science Museum, Nashville, TN, June 2000. *The roles of genetics, aging, and environment in Parkinson's disease.*
19. American Association of Neuropathologists, Atlanta, GA, 2000. *Quantification of free radical damage to brain in Alzheimer's disease.*
20. University of Rochester, Department of Pharmacology, Rochester, NY, 2000. *Reactive intermediates in neurodegeneration.*
21. Oregon Health & Science University, Oregon Center for Complementary and Alternative Medicine in Neurological Diseases Conference, Portland, OR, 2000. *Quantifying oxidative damage in neurodegenerative disease.*
22. Annual Meeting of the American College of Occupational and Environmental Medicine, Nashville, TN, 2000. *Neurotoxicology.*
23. 21st Annual North American Meeting of the Society of Environmental Toxicology and Chemistry, Nashville, TN, 2000. *Endogenous neurotoxins and neurodegenerative diseases.*
24. Health Sciences Teachers Professional Development Day, Metropolitan Nashville High Schools, Nashville, TN, 2000. *Parkinson's disease – causes and treatment.*
25. Parkinson's Disease Grantees Conference, The Parkinson's Institute, Sunnyvale, CA, March

2001. *Biomarkers of Parkinson's disease progression.*
26. Alzheimer's Disease Association, Middle Tennessee Chapter, Nashville, TN, 2001. *Advances in diagnosis, research, and treatment of Alzheimer's disease.*
 27. Emory University, Department of Pathology and Neurology, and Neurodegenerative Research Center, Atlanta, GA, 2001. *Reactive intermediates in neurodegenerative disease.*
 28. Duke University Medical Center, Department of Neurology and Neurobiology, Durham, NC, 2001. *Lipid oxidation products in neurodegeneration.*
 29. University of Washington, Department of Pathology, Seattle, WA, 2001. *Lipid oxidation products in neurodegenerative diseases.*
 30. National Parkinson Foundation International Symposium on Parkinson's Disease Research, San Diego, CA, 2001. *Biomarkers for neurodegenerative diseases.*
 31. Alzheimer's Association, Middle Tennessee Chapter, Physician Education Seminars, Nashville, TN, 2001. *Dementia overview and accurately diagnosing Alzheimer's disease.*
 32. Nashville Mental Health Association, Nashville, TN, 2001. *Neurodegenerative diseases.*
 33. Oregon Health & Science University, Department of Neurology, Portland, OR, 2002. *Mechanisms of oxidative damage in neurodegeneration.*
 34. Michael J. Fox Foundation, New York, NY, 2002. *Catechol thioethers in dopaminergic neurodegeneration.*
 35. Puget Sound Veterans Administration Medical Center, Geriatric Research and Clinical Center, Seattle, WA, 2002. *Neuropathology of neurodegeneration.*
 36. Puget Sound Veterans Administration Medical Center, Geriatric Research and Clinical Center, Seattle, WA, 2002. *Lipids, inflammation, and oxidative damage in Alzheimer's disease.*
 37. Oregon State University, Linus Pauling Institute, Corvallis, OR, 2003. *Strategies to suppress oxidative damage in neurodegeneration.*
 38. University of Washington, Department of Neurology, Seattle, WA, 2003. *Role of oxidative damage in age-related neurodegenerative diseases.*
 39. Friends of Alzheimer's Disease Research, Seattle, WA, 2003. *Current research in experimental therapeutics for Alzheimer's disease.*
 40. Puget Sound Veterans Administration Medical Center, Geriatric Research and Clinical Center, Seattle, WA, 2003. *Current research in neurodegeneration.*
 41. Preclinical Biomarkers of Alzheimer's Disease Symposium, Washington University in St. Louis, St. Louis, MO, 2003. *Oxidative damage.*
 42. University of Washington, Department of Neurosurgery, Seattle, WA, 2003. *Mechanisms of neurodegeneration.*
 43. University of North Dakota, Department of Pharmacology and Experimental Therapeutics, Grand Forks, ND, 2003. *Pharmacologic suppression of neurodegeneration.*
 44. American College of Neuropsychopharmacology, Annual Meeting, San Juan, Puerto Rico, 2003. *Pharmacologic suppression of oxidative damage in the human central nervous system.*
 45. American Society for Investigative Pathology, Annual Meeting, Washington, DC, 2004. *Pharmacologic suppression of innate immunity-mediated neuronal damage.*
 46. Eli Lilly, Co. and Inflammation Research Association, Indianapolis, IN, 2004. *Suppression of*

innate immunity and neuronal oxidative damage in Alzheimer disease.

47. American Society of Radiology, Annual Meeting, Seattle, WA, 2004. *Pathological features of geriatric dementia.*
48. Oregon Health & Science University, Department of Neurology, Portland, OR, 2004. *Late-stage medium spiny neuron dendritic degeneration in Parkinson disease.*
49. 9th International Conference on Alzheimer Disease, Philadelphia, PA, 2004. *Symposium on: inflammation and oxidative damage.*
50. Alzheimer's Association of Alaska, Anchorage, Fairbanks, and Juneau, AK, 2004. *Advances in Alzheimer's disease research.*
51. World Biomarker Congress, Philadelphia, PA, 2005. *Proteomics in the discovery of CSF biomarkers for Alzheimer's disease.*
52. Vanderbilt University, Department of Pharmacology, Nashville, TN, 2005. *Prostaglandin pathway in Alzheimer's disease.*
53. Amgen, Thousand Oaks, CA, 2005. *Prostaglandin pathway in Alzheimer's disease.*
54. National Institute of Environmental Health Sciences, Center Directors Meeting, Nashville, TN, 2005. *Oxidative damage in Alzheimer's disease.*
55. Second International Conference on Neurodegenerative Diseases of Guam and Surrounding Islands, Guam, 2005. *Proteomics of neurodegenerative diseases.*
56. Puget Sound VA Medical Center, Geriatric Research and Education Center, Seattle, WA, 2006. *APOE isoform-specific innate immunity paracrine damage to neurons.*
57. Oregon Health & Science University, Department of Pathology, Portland, OR, 2006. *Proteomics of dementia.*
58. National Institute of Neurological Disorders and Stroke, Bethesda, MD, 2006. *Workshop on mechanisms of vascular cognitive impairment.*
59. 10th International Conference on Alzheimer's Disease, Madrid, Spain, 2006. *Quantitative proteomics of human CSF to discover biomarkers of Alzheimer's disease.*
60. Joint Meeting of Japanese and American Histochemical Societies, Kona, HI, 2006. *Proteomic survey of post-translational modifications in Alzheimer's disease.*
61. Joint Meeting of Japanese and American Histochemical Societies, Kona, HI, 2006. *Workshop: Combined application of laser capture microdissection and high throughput proteomics.*
62. Society for Neuroscience, Atlanta, GA, 2006. *Workshop: Mechanisms of neuron death.*
63. University of Washington, Department of Neurology, Seattle, WA, 2006. *Proteomic investigations of the neurodegenerative disease of Guam.*
64. University of Pittsburgh, Department of Pathology, Pittsburgh, PA, 2007. *Mechanisms of dementia in the elderly.*
65. Columbia University, Alzheimer Disease Research Center, New York, NY, 2007. *Biomarkers of dementia in the elderly.*
66. Genentech, South San Francisco, CA, 2007. *Therapeutic targets in dementia.*
67. The Parkinson's Institute, Sunnyvale, CA, 2008. *Innate immune activation in neurodegeneration.*
68. Winter Eicosanoid Conference, Baltimore, MD, 2008. *Isoprostanooids in white matter injury.*

69. Neurobiology and Behavior Training Program, University of Washington, Seattle, WA, 2008. *Therapeutic targets in Dementia.*
70. American Society of Biochemistry and Molecular Biology, Annual Meeting, San Diego, CA, 2008. *Mechanisms of dementia in the elderly.*
71. Histochemical Society, Annual Meeting, San Diego, CA, 2008. *Proteomics of neuronal inclusions.*
72. National Institute on Aging, Bethesda, MD, 2008. *Modulation of cerebral innate immune response by glial apolipoprotein E isoforms.*
73. Winter Eicosanoid Conference, Baltimore, MD, 2009. *Suppression of free radical injury to brain in patients with Alzheimer's disease.*
74. American Association of Neurology, Seattle, WA, 2009. *Structural and biochemical correlates of dementia in a population-based study.*
75. American Association of Neuropathologists, San Antonio, TX, 2009. *Free radical injury as a therapeutic target in dementia.*
76. American Veterinary Medicine Association, Seattle, WA, 2009. *Brain aging.*
77. Vanderbilt University, Department of Medicine, Nashville, TN, 2009. *Pharmacologic suppression of oxidative damage to brain in patients with dementia.*
78. University of Virginia, Department of Pathology, Charlottesville, VA, 2009. *Pharmacologic targets in dementia.*
79. University of Minnesota, Department of Neurology, Minneapolis, MN, 2009. *Biomarkers and neuropathology in population-based studies of brain aging and dementia.*
80. University of Washington, School of Medicine, Seattle, WA, 2009. *Science in Medicine Lecture: Therapeutic targets in dementia.*
81. XVIII WFN World Congress on Parkinson's Disease and Related Disorders, Miami, FL, 2009. *Cognitive impairment in Parkinson disease.*
82. Cognitive Neuroscience Society 17th Annual Meeting, Montreal, QC, 2010. *Pharmaconeuropathology of brain aging and dementia.*
83. Vascular Mechanisms in Brain Ageing Workshop, Medical Research Council of the United Kingdom and Emory University, Atlanta, GA, 2010. *Microvascular brain injury as a common cause of cognitive impairment and dementia in the elderly.*
84. National Institutes of Health: Lewy Body Disease Biomarker Conference, Bethesda, MD, 2010. *Alzheimer's disease CSF biomarkers in patients with Parkinson's disease.*
85. University of Wisconsin, Department of Pathology, Madison, WI, 2010. *Therapeutic targets in dementia.*
86. Indiana Alzheimer Disease Center Spring Symposium, Indianapolis, IN, 2010. *Proteomic discovery of CSF biomarkers for Alzheimer's disease.*
87. Society of Toxicologic Pathology, Chicago, IL, 2010. *Biomarkers of neurodegenerative disease.*
88. International Congress on Alzheimer's Disease, Honolulu, HI, 2010. *Co-morbid diseases in the dementia syndrome.*
89. McGill University, Montreal, QC, 2010. *Prostaglandin E₂ receptor subtypes in neurodegeneration.*
90. NIH Alzheimer's Center Directors Meeting, San Francisco, CA, 2010. *Update on biomarkers*

for Alzheimer's and non-Alzheimer's dementias.

91. NIH Udall Centers Directors Meeting, Washington, DC, 2010. *Update on cognitive impairment in Parkinson's disease.*
92. University of California at San Francisco, Gladstone Institute, San Francisco, CA, 2010. *Therapeutic targets in dementia.*
93. Parkinson's Action Network, Washington, DC, 2011. *Cognitive impairment in Parkinson's disease.*
94. Alzheimer's Disease Center Director's Meeting, Los Angeles, CA, 2011. *Ecology of aging human brain.*
95. University of California at Irvine, Memory Impairments and Neurologic Disease Institute, Irvine, CA, 2011. *Therapeutic targets for disease that causes dementia.*
96. Mayo Clinic, Department of Pathology, Rochester, MN, 2011. *Therapeutic targets for disease that causes dementia.*
97. Mayo Clinic, Department of Neurology, Rochester, MN, 2011. *Ecology of aging human brain.*
98. International Conference on Alzheimer's Disease, Paris, France, July 2011. *National Institute on Aging-Alzheimer's Association revised criteria for the neuropathologic evaluation of Alzheimer's disease.*
99. Society for Neuroscience, Satellite meeting on Parkinson's Disease sponsored by Covance, Washington, DC, 2011. *Risk assessment and biomarkers for Parkinson's disease.*
100. UCLA, Mary S. Easton Center for Alzheimer's Research, Los Angeles, CA, 2011. *Therapeutic targets for diseases that cause dementia.*
101. XI National Parkinson Foundation Symposium on Parkinson's Disease: Targeting Non-Motor Symptoms, Washington, DC, 2011.
102. AstraZeneca, Workshop on Neuroinflammation in Alzheimer's Disease, Södertälje, Sweden, 2011. *Innate immune activation in the pathogenesis of Alzheimer's Disease,*
103. Pennsylvania State University Medical School, Department of Pathology, Hershey, PA, 2012. *Ecology of aging human brain.*
104. Pennsylvania State University Medical School, Department of Pathology, Hershey, PA, 2012. *Therapeutic targets for diseases that cause dementia.*
105. American Academy of Neurology, New Orleans, LA, 2012. *Biomarkers in Neurological Diagnosis and Therapeutic Monitoring.*
106. American Association of Neuropathologists, Chicago, IL, 2012. *Revised National Institute on Aging-Alzheimer's Association Guidelines for the Neuropathologic Assessment of Alzheimer's Disease and Related Dementias.*
107. Northwestern University, Department of Physiology, Chicago, IL, 2012. *Ecology of Aging Human Brain.*
108. University of Rochester, Department of Pathology, Rochester, NY, 2012. *Therapeutic Targets for Dementia.*
109. Western & Central WA Chapter of the Alzheimer's Association, Seattle, WA, 2013. *Alzheimer's Disease.*
110. Feinstein Institute, Northshore-Long Island Jewish Medical Center, Manhasset, NY, 2013. *Therapeutic Targets for Dementia.*
111. Friday Harbor Symposium, San Juan Island, WA, 2013. *Ecology of Aging Human Brain.*
112. University of Chicago, Department of Pathology, Chicago, IL, 2013. *Ecology of Aging Human Brain.*

113. University of Southern California, Los Angeles, CA 2013. *Therapeutic Targets for Dementia.*
114. Massachusetts General Hospital, Boston, MA, 2013. *Precision Medicine for Diseases that Cause Dementia.*
115. Vanderbilt University, Nashville, TN, 2013. *Precision Medicine for Diseases that Cause Dementia.*
116. NINDS workshop: Vascular Contributions to Alzheimer's Disease and Dementia, Alzheimer's Association, Chicago, IL, December 2013. *Underlying Pathogenesis and Animal Models.*
117. Keystone Symposium, Keystone, CO, March 2014. *Modifiable Factors Associated with Free Radical Injury to Brain.*
118. Keystone Symposium, Keystone, CO, March 2014. *Update on NINDS ADRD and PD Conferences.*
119. Western Washington University, Bellingham, WA, May 2014. *Therapeutic Imperative for Alzheimer's Disease.*
120. American Association of Neuropathologists, Annual Meeting, Portland, OR, June 2014. *Saul Korey Lecture: Alzheimer's Disease and Related Dementias.*
121. University of California at Irvine, Annual Alzheimer's Disease Symposium, Irvine, CA, September 2014. *Alzheimer's Disease and Related Dementias.*
122. Columbia University, Department of Pathology and Cell Biology, New York, NY, September 2014. *Precision Medicine for Alzheimer's and Parkinson's Diseases.*
123. Massachusetts General Hospital, Department of Neurology, Boston, MA, October 2014. *Dr. Raymond Adams Lecture: Precision Medicine for Alzheimer's and Parkinson's Diseases.*
124. Cold Spring Harbor, NY, November 2014. *Dopaminergic denervation and Alzheimer's disease penetrance.*
125. University of Pennsylvania, Department of Pathology, Philadelphia, PA, January 2015. *Precision Medicine for Alzheimer's and Parkinson's Diseases.*
126. University of Wisconsin, Alzheimer's Disease Research Day, Madison, WI, March 2015. *Precision Medicine: Clarity for the Complexity of Dementia.*
127. Peking University, 11th Forum of Mainland and Overseas Pathologists, Beijing, China, April 2015. *Precision Medicine: Clarity for the Complexity of Dementia.*
128. Peking University, 11th Forum of Mainland and Overseas Pathologists, Beijing, China, April 2015. *Case studies in neurodegenerative causes of dementia.*
129. Experimental Biology 2015, American Society for Investigative Pathology, Presidential Symposium, March 2015. *Precision Medicine: Clarity for the Complexity of Dementia.*
130. Alzheimer's Association International Conference, Washington DC, July 2015. Invited Plenary talk: *Biochemically based quantitative neuropathology in clinical cohorts.*
131. National Academy of Medicine, Washington DC, October 2015. *Aging Brain and Neurodegeneration.*
132. Alzheimer's Association Roundtable, Washington DC, October 2015. *Tau Pathologies and Different Tauopathies.*
133. International Dementia with Lewy Body Disease Conference, Fort Lauderdale, FL, December 2015. *DLB Research in North America.*
134. Brain Rejuvenation Program, Stanford University, CA, May 2016. *Precision Health: Clarity for the Clinical and Biological Complexity of Parkinson's Disease.*
135. Stanley Aronson, MD, Visiting Lectureship in Neurology, Brown University, Providence, RI, June 2016. *Precision Health: Clarity for the Clinical and Biological Complexity of Dementia.*
136. Alzheimer's Association Annual Research Symposium, UC Davis, July 2016. *Precision Health: Clarity for the Clinical and Biological Complexity of Dementia.*
137. New York Academy of Medicine – Frontiers in Neuropathology, September 2016. *Alzheimer's Disease.*

138. World Parkinson Congress, Portland, OR, September 2016. *Genetic Risk for Cognitive Impairment in Parkinson's Disease.*
139. UCSF Center for Imaging Neurodegenerative Diseases, San Francisco, CA, October 2016. *Precision Health: Clarity for the Clinical Complexity of Parkinson's Disease.*
140. BrightFocus, Alzheimer's Fast Track, San Diego, CA, November 2016. *Neuropathology of Alzheimer's Disease.*
141. Emory University, Atlanta, GA, January, 2017. *Synaptic Pathology in Brain Aging and Neurodegeneration.*
142. Mayo Clinic, Jacksonville, FL, March 2017. *Synaptic Pathology in Brain Aging and Neurodegeneration.*
143. Columbia University, NY, April 2017. *Synaptic Pathology in Brain Aging and Neurodegeneration.*
144. Parkinson's Progression Marker Initiative, NY, May 2017. *Neuropathology.*
145. Dublin Clinical Neurosciences Conference, Dublin Ireland, August 2017. *Cognitive Impairment in Parkinson's Disease.*
146. Wake Forest University, Department of Pathology, Winston-Salem, NC, September 2017. *Synaptic Pathology in Brain aging and Neurodegeneration.*
147. Charite Medical Center, Institute of Pathology, Berlin, Germany, October 2017. *(Re)Building Academic Pathology.*
148. San Francisco Neuroscience Society, San Francisco, CA, November 2017. *White Matter and Dementia.*
149. University of Pennsylvania, Institute on Aging, Philadelphia, PA, November 2017. *Synaptic Pathology in Brain aging and Neurodegeneration.*
150. Alzheimer's Association Research Roundtable, Washington DC, November 2017. *Amyloid: Necessity vs. Sufficiency.*
151. Becton Dickinson, San Jose, CA, September 2018. *Biomarkers for Alzheimer's Disease.*
152. University of Michigan, Department of Neurology, Ann Arbor, MI, October 2018. *Synaptic Pathology in Brain aging and Neurodegeneration.*
153. University of Pittsburgh, Department of Pathology, Pittsburgh, PA, November 2018. *Parkinson's Disease is a Systemic Neurodegenerative Disorder.*
154. Technion University, Rambam Health Care Campus, Haifa, Israel, January 2019. *Genetics and Biobanking.*
155. University of California at San Diego, San Diego, CA, February 2019. *Synaptic Pathology in Brain Aging and Neurodegeneration.*
156. Universite de Barcelona, Barcelona, Spain, April 2019. *Brain Aging and Neurodegeneration.*
157. Universite de Montpellier, Montpellier, France, April 2019. *Free Radical Injury in Brain Aging and Neurodegeneration.*
158. Cedars Sinai Medical Center, Los Angeles, CA, April 2019. *Leo Kaplan, M.D., Lecture in Anatomic Pathology: Cognitive Impairment in Parkinson's Disease.*
159. Parkinson's Progression Marker Initiative, New York, NY, May, 2019. *Neuropathology of Parkinson's Disease.*
160. Emory University, Department of Neurology, Atlanta, GA. May 2019. *Brain Aging and Neurodegeneration.*
161. Emory University Udall Center Annual Keynote, Atlanta, GA, May 2019. *Genetic Risk for Cognitive Impairment in Parkinson's Disease.*
162. 5th World Parkinson's Congress, Kyoto, Japan, June 2019. *Neuropathology of cognitive deficits in PD and its insights into therapeutic interventions.*
163. University of Leuven, Leuven, Belgium, July 2019. *ApoE Isoforms in Brain Aging and Neurodegeneration.*

164. 1st NIH Workshop on *Cognitive Reserve and Resilience*, September 2019. *Alzheimer's Disease and Related Dementias*.
165. NIH Workshop, November 2019. *Neuropathological Diagnosis of Chronic Traumatic Encephalopathy (CTE): Next Steps*.
166. Alzheimer's Association International Conference, Amsterdam, July 2020. *Mass Synaptometry in Alzheimer's Disease* (switched to virtual because of COVID-19).
167. Stanford-Kanagawa Annual Symposium, Kyoto, Japan, November 2020. *Diagnostics and Testing for COVID-19* (switched to virtual because of COVID-19).
168. 15th International Conference on Alzheimer's & Parkinson's Diseases (ADPD), Barcelona, Spain, March 2021. *Resistance, Reserve, and Resilience in Neurodegeneration* (switched to virtual because of COVID-19).

PUBLICATIONS

Research Manuscripts

Bibliometrics

PubMed lists **694 research publications** for Dr. Montine in reverse chronological order. Go to <http://www.ncbi.nlm.nih.gov/pubmed> and enter "montine t" in the search box.

Google Scholar lists Dr. Montine's publications by number of times cited and estimates his **H Index = 121** and **total citations > 79,000**. Go to <http://scholar.google.com/> and enter "Montine" in the search box.

NIH iCite calculates Dr. Montine's **weighted relative citation ratio as 3453**.

Book Chapters

1. Borch RF, Dedon PC, **Montine TJ**. *Experimental approaches to reducing platinum induced kidney toxicity*. In: *Organ Directed Toxicities of Anticancer Drugs*, eds. MP Hacker, JS Lazo, TR Tritton. 1987, Boston, MA: Martinus Nijhoff. pp 190-202.
2. Borch RF, Dedon PC, Gringeri A, **Montine TJ**. *Inhibition of platinum drug toxicity by diethyldithiocarbamate*. In: *Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy*, ed. M Nicolini. 1987, Boston, MA: Martinus Nijhoff. pp 216-27.
3. **Montine TJ**, Valentine W, Graham DG. *Central and peripheral nervous systems*. In: *Pathology of Environmental and Occupational Disease*, ed. J Craighead. 1994, Philadelphia, PA: Mosby. pp 511-30.
4. **Montine TJ**, Hulette CM. *Pathology of ischemic cerebrovascular disease*. In: *Neurosurgery* (2nd edition), eds. RH Wilkins, SS Rengachary. 1995, New York: McGraw-Hill. pp 2045-51.
5. Anthony DC, **Montine TJ**, Graham DG. *Nervous system*. In: *Casarett and Doull's Toxicology* (5th ed), eds. MO Amdur, J Doull, CD Klassen. 1995, New York: Pergamon Press. pp 463-86.
6. Morrow JD, Tapper AR, Zackert WE, Yang J, Sanchez SC, **Montine TJ**, Roberts LJ. *Formation of novel isoprostane-like compounds from docosahexaenoic acid*. In: *Proceedings of the Fourth International Conference on Eicosanoids in Inflammation and Cancer*. 1997, New York, NY: Plenum Press.
7. Johnson MD, Kim PJ, **Montine TJ**, Maciunas RJ. *Stereotactic biopsies: pathological*

- considerations*. In: Advanced Neurosurgical Navigation, eds EB Alexander, RJ Maciunas. 1998, New York, NY: Thieme Medical Publishers. pp 17-29.
8. Graham DG, Picklo MJ, Zhang J, **Montine TJ**. *Role of quinones in catechol neurotoxicity*. In: Role of Catechol Quinone Species in Cellular Toxicity, ed. CR Creveling. 1999, Johnson City, TN: FP Graham Publishing. pp 31-40.
9. **Montine TJ**, Amarnath V, Picklo MJ, Sidell KR, Zhang J, Graham DG. *Endogenous brain catechol thioethers in dopaminergic neurodegeneration*. In: Neurotoxic Factors in Parkinson's Disease and Related Disorders, eds. A Storch, MA Collins. 2000, New York, NY: Plenum Publishers. pp 155-66.
10. Anthony DC, **Montine TJ**, Graham DG. *Nervous system*. In: Casarett and Doull's Toxicology (6th edition), eds. MO Amdur, J Doull, CD Klaassen. 2001, New York, NY: Pergamon Press. pp 535-64.
11. **Montine TJ**, Markesbery WR, Lovell, MA. *Oxidative alterations in neurodegenerative diseases*. In: Pathogenesis of Neurodegenerative Disorders, ed. MP Mattson. 2001, Totowa, NJ: Humana Press. pp 21-52.
12. Morrow JD, Reich EE, Roberts LJ, **Montine TJ**. *Quantification of isoprostanes as an index of oxidant stress status in vivo*. In: Critical Reviews of Oxidative Stress and Aging: Advances in Basic Science, Diagnostics, and Interventions. eds RG Cutler, H Rodriguez. 2001, River Edge, NJ: World Scientific Publishing. Chapter 22.
13. Morrow JD, Zackert WE, Van der Ende DS, Reich EE, Terry ES, Cox B, Sanchez SC, **Montine TJ**, Roberts LJ. *Quantification of isoprostanes as indicators of oxidant stress in vivo*. In: Handbook of Antioxidants (2nd edition), ed. E Cadenas. 2001, pp 57 - 74.
14. **Montine TJ**, Hulette CM. Pathology of ischemic cerebrovascular disease. In: Neurosurgery (3rd edition), eds. SS Rengachary, RJ Maciunas, RH Wilkins. 2001, NY: McGraw-Hill.
15. Atkinson JB, Johnson MD, **Montine TJ**, Whetsell WO. Muscle and nerve biopsy. In: Modern Surgical Pathology, eds. N Weidner, et al. 2002, Philadelphia: W.B. Saunders. Chapter 53.
16. **Montine TJ**, Graham DG. *Toxic disorders*. In: Greenfield's Neuropathology (7th edition), eds. DI Graham and P Lantos. 2002, London: Arnold. pp 799-822.
17. Montine KS, Quinn JF, **Montine TJ**. Membrane lipid peroxidation. In: Membrane Lipid Signaling in Aging and Age-Related Disease, ed. MP Mattson. 2003, Elsevier. pp 11-26.
18. Zhang J, **Montine TJ**. *Oxidative processes*. In: Primer on the Autonomic Nervous System, (2nd edition), ed. D Robertson. 2004, Amsterdam: Elsevier. pp 201 - 203.
19. **Montine TJ**. Pathophysiology of geriatric dementia. American Society of Neuroradiology, 2004.
20. Bassett C and **Montine TJ**. *Lipoproteins and lipid peroxidation in Alzheimer's disease*. In Research and Practice in Alzheimer's Disease Collection: Nutrition, Cognitive Decline, and Aging. 2005, New York: Springer Publishing. pp 127 - 139.
21. **Montine TJ**, Alvord, EC Jr., Shaw C-M. *Nervous system disorders*. In: McGraw-Hill Encyclopedia of Science & Technology (10th edition), 2007.
22. Keene CD, Cimino PJ, Breyer RM, Montine KS, **Montine TJ**. *E prostanoid receptors in brain physiology and disease*. In: Genomics, Proteomics and the Nervous system. Clelland JD, ed. Volume 13 of Handbook of Neurochemistry and Molecular Neurobiology, 3rd edition. 2009, New York, Kluwer Publishing.
23. Andreasson K and **Montine TJ**. *Arachidonic acid metabolites: function in neurotoxicity and inflammation in the central nervous system*. In: CNS Diseases and Inflammation eds. T.

- Lane, M Carson, C Bergmann, and T Wyss-Coray. 2007, Springer: pp 107-130.
24. Sonnen JA, Keene CD, Hevner RF, **Montine TJ**. *Pathology of the central nervous system*. In: Molecular Pathology ed. W. Coleman. 2009, Elsevier: pp 551 - 590.
 25. Milatovic D, Zaja-Milatovic S, Breyer RM, Aschner M, **Montine TJ**. *Neuroinflammation and oxidative injury in developmental neurotoxicity*. In: Reproductive and Developmental Toxicology, ed R. Gupta. 2011, Academic Press, London. pp.847-854.
 26. **Montine TJ** and Anthony DC. *Toxicologic neuropathology in medical practice*. In: Fundamental Neuropathology for Pathologists and Toxicologists: Principles and Techniques, eds. B Bolon and M Butt. 2011, Hoboken NJ: John Wiley and Sons. pp 475-486.
 27. Schneider JA, **Montine TJ**, Sperling RA, and Bennett DA. *Neuropathological basis of Alzheimer's disease and Alzheimer's disease diagnosis*. In: Alzheimer's Disease – Modernizing Concept, Biological Diagnosis and Therapy, eds. H. Hampel and M. Carrillo. 2012, Karger, Basel. pp 49-70.
 28. Baird GS and **Montine TJ**. *Clinical laboratory investigations in geriatric neurology*. In: Geriatric Neurology, eds A. K. Nair and M. N. Sabbagh. 2014, Hoboken NJ: John Wiley and Sons. pp 170-180.
 29. Cudaback E, Cholerton B, Montine KS, **Montine TJ**. *Neuropathology, biomarkers and cognition in Parkinson's disease*. In: Clinical Neuropsychology and Cognitive Neurology of Parkinson's Disease and Other Movement Disorders. ed. A. Troster. 2014, Oxford University Press, New York. pp 129-147.
 30. Keene CD and **Montine TJ**. *Alzheimer's Disease and Related Dementias*. In: UpToDate
 31. Latimer C and **Montine TJ**. *Dementia with Lewy Bodies*. In: UpToDate

Edited Books and Special Edition Journals

32. Eicosanoids and docosanoids in CNS disease. Symposium, *Brain Pathol* 2005; 15(2). Guest Editor: **Thomas J. Montine**.
33. Biomarkers for Alzheimer's disease. Special edition, *J Alzheimers Dis*, 2005; 8(4). Guest Editor: **Thomas J. Montine**
34. Proteomics of Neurodegenerative Diseases. Research Signpost, 2006. Editor: **Thomas J. Montine**
35. Dementia in Parkinson's disease. Minisymposium, *Brain Pathol* 2010; 20(3). Guest Editor: **Thomas J. Montine**.
36. Clinical-pathologic correlations in population- and community-based studies of brain aging. Mini-forum, *J Alzheimers Dis* 2009; 18(4). Guest Editors: **Thomas J. Montine** and Joshua Sonnen.

Media

37. Montine TJ and Burke W. Guest column: 'Precision medicine' offers promise of personalized care. Puget Sound Business Journal. 12 August 2013.

TRAINEES**Doctoral Thesis Advisor**

Past and Current Trainees	Training Period
Casey Bassett, PhD	1996-2001
Erin Reich, PhD	1996-2001
Kathrin Sidell, MD, PhD (MSTP)	1997-2001
Joyce Ou, MD, PhD (MSTP)	1997-2002
Vanessa Fitsanakis, PhD	2000-2003
Angela Boutte, PhD	2001-2005
Izumi Maezawa, PhD	2002-2005
PJ Cimino, MD, PhD (MSTP)	2005-2011
Laura Snyder, PhD	2005-2010
Amalia Perna, PhD	2016-2021

Postdoctoral Fellows

Past Trainees	Training Period	Current Trainees	Training Period
Matthew J. Picklo, PhD	1997-2001	Adam Wawaro, PhD	2017 - present
Dejan Milatovic PhD	2001-2004	Dunja Mrden, PhD	2018 - present
Feng Shie, PhD	2002-2005	Katherine Lucot, PhD	2018 - present
Anke Witting, PhD	2005 - 2007	Robert Lesniak, PhD	2018 - present
Angela Guillozet-Bongaarts, PhD	2007-2008	Joe Phongpreecha, PhD	2018 - present
Di Ngyen, PhD	2006-2007	Amalia Perna	2019 - present
Nadia Postupna, PhD	2009-2010		
James Li, PhD	2009-2011		
Eiron Cudaback, PhD	2009		
Catherine Hagan, D.V.M., PhD	2010		
W. Michael Caudle, PhD	2007- 2010		
Erica Melief, PhD	2011 - 2015		
Garrett Morgan, PhD	2013 - 2015		
Ryan Corces, PhD	2016 - 2020		
Anna Lena Lang, MD	2018 - 2019		

Neuropathology Fellows

Past Trainees	Training Period	Past Trainees	Training Period
Jing Zhang, MD, PhD	1997 - 1999	Josh Sonnen, MD	2005-07
Xuemo Fan, MD, PhD	1998 - 2000	Christopher Keene, MD, PhD	2006-08
Tibor Valy-Nagy, MD, PhD	1999 - 2001	Joseph Fullmer, MD, PhD	2007-09
Randall Woltjer, MD, PhD	2000 - 02	B. Russ Huber, MD, PhD	2008-10
John Matthew Lacy, MD	2002-03	Luis F. Gonzalez-Cuyar, MD	2009-11
Rory Donnellan, MBChB	2003-04	Caitlin Latimer, MD, PhD	2015-2017
Imran Umar, MBBS.	2004-06	Margaret Flanagan, MD	2015-2017